45 results about "Paclitaxel Injection" patented technology

The present invention relates to a method for the preparation of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby, the paclitaxel solid dispersion being highly homogeneous and showing an improved solubility, thereby being effectively used for the preparation of paclitaxel injection and oral preparation having a high bioavailability.

The invention discloses a paclitaxel mixed micelle preparation, comprising 100 to 300 milligram of tocopherol polyethylene glycol succinate 1000 (TPGS), 0 to 50 milligram of phosphatide, 0.5 milliliter of anhydrous ethanol and 6 milligram of paclitaxel. The preparation method is as follows: the TPGS is dissolved in the anhydrous ethanol, or the TPGS and the phosphatide are dissolved in the anhydrous ethanol; the paclitaxel is added and dissolved under stirring; the mixture is filtered with a millipore filtration of 0.22 micrometer so as to obtain the paclitaxel mixed micelle preparation. In the invention, the TPGS and the phosphatide are used to form mixed micelles which have good stability and little toxic and side effects; the preparation method is simple and practicable, having a good application prospect. Compared to the prior art, polyoxyethylene castor oil in conventional prescription is substituted in the invention, thereby reducing toxic side effects of paclitaxel injections and greatly enhancing the safety of the injections on condition that solubility is guaranteed.

The invention relates to a DSPE-PEG2000-FA-modified nanometer paclitaxel liposome. A molar ratio of the DSPE-PEG2000-FA to egg yolk lecithin is 0.05% to 0.15%, and a particle size of the liposome is less than 150 nm. A preparation method of the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome comprises the following steps: first, preparing a DSPE-PEG2000-FA into a DSPE-PEG2000-FA micelle; second, performing incubation on the phosphatidyl ethanolamine-polyethylene glycol2000-folic acid micelle and a paclitaxel liposome together to obtain a DSPE-PEG2000-FA-modified nanometer paclitaxel liposome. Materials, which are forbidden to be used in clinical practice, are not used as crude materials in the present invention. According to the invention, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome has a small particle size, and the content of the DSPE-PEG2000-FA is low; besides, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome has good drug entrapment efficiency and good colloid stability. Moreover, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome can be absorbed effectively by an ovarian cancer cell having properties of sensitiveness to folic acid (+) and drug resistance, and the cytotoxicity of folic acid dependence is displayed; therefore, the efficacy of the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome is stronger than that of a paclitaxel injection.

The invention relates to a paclitaxel injection and a preparation method of the injection: (1) 200 to 400ml of absolute alcohol and 200 to 400ml of normal saline are taken to be stirred, and 150 to 400ml of polyethylene glycol 400 is added to be evenly mixed; (2) 20 to 40g of tween-80 is added in to the mixture of (1) to be evenly mixed, and then 0.2 to 0.5g of active carbon used for injection is added to be heated by 35 to 40 DEG C, and raw filtering is carried out and the PH value is controlled to be between 3 to 5; filtering is done and filling and sealing process is carried out; sterilization is carried out for 20 to 35 minutes at the temperature of 100 to 125 DEG C; (3) a transfusion bottle is washed and then is dried for 25 to 35 minutes the temperature of 230 to 260 DEG C, and butyl rubber plug is sterilized; (4) 0.6 to 3g of paclitaxel is taken to be added into the mixture of (2) for dissolving, and then sterilization and filtering are done; and then the solution is filled into the transfusion bottle in the sterilized environment; finally, the bottle is sealed to get the finished product. The invention can prepare safe and reliable paclitaxel injection, by adopting the method of preparing menstruum firstly and paclitaxel solution secondly, the quality of the injection is guaranteed.

The invention relates to a paclitaxel lipid microsphere injection and a manufacturing method thereof. In the invention, a paclitaxel lipid microsphere injection that does not contain polyoxyethylene castor oil is prepared. The medicine 90-98 per cent paclitaxel is coated in the oil phase and the oil-water interfacial film of the lipid microsphere. Thus the toxicity and stimulation of paclitaxel in clinic use are largely reduced, and the adverse reaction resulted from the excipient in the existing paclitaxel injection is prevented. With low stimulation, low toxicity and high efficiency, the preparation as a antineoplastic drug is administrated by intravenous injection.

The invention belongs to the technical field of biomedicines, and relates to a paclitaxel entrapped polymeric micelle for treating tumors, and a preparation method thereof. The preparation method comprises the following steps: preparing paclitaxel PEG-PLA/Vitamin E-TPGS mixed micelle through adopting a film dispersion technology, and entrapping paclitaxel into the hydrophobic core of the mixed micelle by using the mixed micelle composed of PEG-PLA and Vitamin E-TPGS as a carrier. The prepared paclitaxel paclitaxel PEG-PLA/Vitamin E-TPGS mixed micelle can effectively increase the solubility of paclitaxel and substantially improves the paclitaxel load of a micelle system to reach 35% (w/w), and Vitamin E-TPGS in the mixed micelle system has a P-gp efflux inhibition biologic function, and can efficiently reverse the multidrug resistance of tumors in order to improve the tumor treatment effect. The mixed micelle does not contain Tween80 or ethanol; and compared with commercial paclitaxel injections, the above preparation provided by the invention has the advantages of no allergy of commercial preparations, reduction of toxic side effects, and increase of the safety of clinic application.

The invention belongs to the technical field of biological medicines and relates to a paclitaxel-entrapped biodegradable nanocomposite and a preparation method thereof. A paclitaxel polyethylene glycol-poly trimethylene carbonate (PEG-PTMC) nanocomposite is prepared by adopting an emulsification/solvent evaporation method, and by taking a PEG-PTMC copolymer as a carrier, paclitaxel is entrapped in a hydrophobic core of PTMC. The solubility of the paclitaxel can be effectively increased by the prepared paclitaxel PEG-PTMC nanocomposite, and a PEG long chain of a carrier material can take effect of invisibility, and thereby, the phagocytosis of an in-vivo reticulo-endothelial system is avoided. The nanocomposite has a long circulation effect, and the half-life period of the nanocomposite in blood can be prolonged. Moreover, through controlling the grain size of the nanocomposite, a passive targeting effect on a tumor tissue is realized, and thereby, a treatment effect is improved. As the nanocomposite does not contain Cremophor El or ethanol, compared with commercially available paclitaxel injections, the toxic and side effects of the nanocomposite can be reduced, and the safety of the nanocomposite in clinical application is enhanced.

The invention discloses a TPE material for medical infusion device tube and a preparation method thereof. The TPE materials includes the following raw materials by weight: 100 portions of SEBS, 30 portions of co-polypropylene, 20 portions of oleamide and 1 portion of an antioxidant. The medical infusion device tube prepared from the TPE material has no adsorption effect on many drugs, so that drug dosage accuracy and the therapeutic effect are guaranteed; and the problem of participation of released paclitaxel injection and the polyoxyethylene castor oil in plasticizing agent in the reaction are avoided, so as to ensure the use effect of anti-cancer drug such as paclitaxel. In addition, the medical infusion device tube can avoid the problem of migration of processing aid or plasticizer into the blood or in medical liquid, and the important indexes including pH value variation, reducing substances, heavy metal content, cell toxicity, UV absorbance, sensitization response and hemolytic reaction are superior to those of the similar polyvinyl chloride products, so as to ensure the safety of patients.

The invention relates to a pharmaceutical preparation composition, in particular to a pharmaceutical composition containing a paclitaxel injection. The pharmaceutical composition consists of paclitaxel, sodium acetylsalicylate, 1,2-propylene glycol and absolute ethyl alcohol.

The invention discloses a taxol microemulsion drug composition and a preparation method thereof. The drug composition comprises the following active ingredients: taxol, an oil phase, a solubilizing agent, a stabilizing agent, an excipient, an acidity regulator and water for injection and is characterized in that the main grain size of taxol microemulsion ranges from 10nm to 40nm; and the parts by weight of taxol, an emulsifying agent, the oil phase and the water phase are respectively 30, 1500-3000, 100-350 and 5000-50000. The drug composition has the beneficial effects that taxol is taken as the main drug and different auxiliary materials are added to prepare microemulsion; the taxol microemulsion freeze-dried preparation prepared through freeze drying has good water solubility and stability; the clinical defect of severe allergic reaction of the taxol injection in the market is overcome; meanwhile, the preparation process is simple and is suitable for industrial mass production; and a new administration dosage form is provided for clinical application of taxol.

The invention relates to a pharmaceutical composition using liensinine to work in coordination with paclitaxel for chemotherapy and an application method of the pharmaceutical composition. The pharmaceutical composition comprises a liensinine injection solution and a chemotherapy drug paclitaxel injection solution. The application method comprises the following steps: (1) performing intravenous injection of liensinine once daily according to the dose that actual dosage in the liensinine injection solution to the body weight of a patient is equal to 4.88mg/kg; (2) performing intravenous injection of paclitaxel once according to the dose that the actual dosage in the paclitaxel injection solution to the body weight of the patient is equal to 2.562mg/kg on the day of injecting liensinine according to the step (1); (3) performing intravenous injection of the paclitaxel injection solution once again according to the dose in the step (2) on the twenty-second day; and (4) determining whether to circulate according to the method of the steps (1)-(3) or not, the number of circulation times and the intermediate drug withdrawal time from the forty-third day according to the bearing capacity and the treatment effect of a patient body. Compared with the prior art, in the aspect of inhibiting and killing various malignant tumor cells, the pharmaceutical composition provided by the invention has the advantages of reducing the dosage, shortening the treatment period and reducing the occurrence of toxic and side reactions.

The invention provides paclitaxel lipid nanoparticle injection liquid, which comprises paclitaxel medicine, lipid materials, water for injection, surfactant, stabilizers and metal ion chelating agents. Most medicine is wrapped inside lipid, the direct contact between the medicine and blood or other liquid is avoided, and the local irritation of the medicine on the injection position is reduced, and the toxicity is reduced. No any organic solvents are contained, no solvents with toxicity and irritation on human bodies are contained, and no irritation and no sensitization are caused on the human bodies. The adverse reaction of the existing preparation caused by the recipe problem can be eliminated, and the goals of safety and efficiency are reached. Meanwhile, the paclitaxel lipid nanoparticle injection liquid has the excellent characteristic that the tumor medicine resistance is overcome, and the cure efficiency of the paclitaxel on the existing various tumors is greatly improved.

The invention relates to a preparation method of paclitaxel injection resistant to terminal sterilization, belonging to the technical field of pharmaceutical preparations. The preparation method of the paclitaxel injection comprises the following steps: (1) adding a prescribed amount of paclitaxel into a prescribed amount of polyoxyethylene (35) castor oil, and stirring and shearing at a high speed; (2) adding a prescribed amount of absolute ethanol into the solution, stirring until the solution is mixed evenly, and deoxidizing; (3) sterilizing and filtering the solution obtained in the step (2), filling and deoxidizing, sealing, and carrying out high temperature sterilization. The preparation method of the paclitaxel injection enables the paclitaxel to be wrapped by the polyoxyethylene (35) castor oil by changing a feeding sequence, so that the material degradation and decomposition of the paclitaxel can be reduced in a terminal sterilization process, and the finally obtained paclitaxel injection is good in quality and high in stability.

According to the preparation method of the paclitaxel injection with the stable property, the blank auxiliary materials are pretreated, carboxylate anions in the auxiliary materials are reduced, degradation of main components is inhibited, and the stability of the paclitaxel injection in the storage period is improved; meanwhile, introduction of a pH regulator is avoided, the pH value of the obtained preparation is 4-6, in the pH value range of infusion tolerable by the human body, adverse reactions can be reduced, and the compliance and safety of the medicine in the clinical use process are improved. Besides, finished products which are prepared from domestic and imported polyoxyethylene 35 castor oil and have obvious difference in quality can achieve similar stability, are consistent with related substances of a reference preparation in level and are good in stability, and the safety of the products in the using process can be effectively guaranteed.

The invention relates to the technical field of anti-tumor drugs and particularly relates to an anti-tumor pharmaceutical composition as well as a preparation method and application thereof. By utilizing the anti-tumor pharmaceutical composition prepared from refined polyoxyethylated castor oil, the occurrence rate of serious untoward effects of a taxol injection is decreased, and the pharmaceutical safety and the pharmaceutical compliance of a patient are improved. The comparison of impurities before and after the polyoxyethylated castor oil is refined shows that the contents of polyoxyethylated castor oil impurities at relative retention time 0.6 and 1.2 in a related substance related substance of the taxol injection are remarkably reduced, and the safety of the refined polyoxyethylatedcastor oil is obviously improved.

The invention relates to a pharmaceutical composition of paclitaxel and ranitidine hydrochloride, and especially relates to an application product of the pharmaceutical composition, wherein the application product comprises paclitaxel injection and an injection containing ranitidine hydrochloride. Administration comprises following steps, the injection containing ranitidine hydrochloride is applied firstly by intravenous injection, the paclitaxel injection is dissolved and diluted by normal saline or 5% glucose and sodium chloride solution, and then the diluted paclitaxel injection is applied by intravenous drop infusion.

The invention provides a preparation method of a paclitaxel dressing bin. The preparation method comprises the steps: after uniformly mixing paclitaxel, lecithin and various accessories, coating on bottom cotton and medicine cotton, finally preparing the bin, and applying to a focus position by using an ultrasonic 3 MHZ guide instrument during use. The preparation method is low in cost, and simple in process; the prepared paclitaxel dressing bin is used for preventing and controlling breast cancer, and applied to the focus position by arranging the ultrasonic 3 MHZ guide instrument. The toxic and side effects of an existing paclitaxel injection are overcome.